In this study, we established the GMII consisting of eight glutamine metabolism-related genes (ENPP1, GALK1, TALDO1, CYP19A1, FASN, AHCY, SLC7A9, and HSPG2), a high value of which is associated with poor prognosis in bladder cancer patients. This evidence concerns the gene TALDO1 and urinary bladder carcinoma.